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Summary
Osteoporosis and atherosclerosis are linked by biological as-
sociation. This encourages the search for therapeutic strate-
gies having both cardiovascular and skeletal beneficial ef-
fects. Among drugs that may concordantly enhance bone den-
sity and reduce the progression of atherosclerosis we can in-
clude bisphosphonates (BP), statins, β-blockers, and possibly
anti-RANKL antibodies. Available data come from experimen-
tal animals and human studies. All these treatments however
lack controlled clinical studies designed to demonstrate dual-
action effects.
KEY WORDS: osteoporosis, atherosclerosis, bisphosphonates, β-blockers,
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Introduction
Among the degenerative conditions occurring with aging, os-
teoporosis and atherosclerosis are critical healthy problems.
The role these chronic diseases play in the decline in quality of
life and as a major cause of morbidity and mortality can not be
overlooked. From a clinical point of view, both osteoporosis
and atherosclerosis are silent illnesses, that may remain as-
ymptomatic until a fragility fracture or a thrombotic obstruction
occurs. Although osteoporosis and cardiovascular diseases
have been considered independent processes, increasing evi-
dence suggests the existence of a biological linkage between
bone and vascular system. The association between bone
mass loss and carotid atherosclerosis, coronary artery disease,
arterial disease of lower limbs, and aortic calcification has been
demonstrated in several studies (1-5). Some of them show that
the progression of the arterial plaque parallels bone loss, how-
ever the nature of the possible link remains uncertain. Several
hypotheses have been suggested to explain this association,
which include age-related mechanisms, diabetes mellitus, es-
trogen deficiency, hypovitaminosis D and K, cigarette smoking,
and renal failure (6). Inflammatory cytokines and oxidized LDL
have been suggested as crucial determinants of both calcifica-
tion in the vascular intima and reduction in osteoblast activity
(7). The existence of an age-independent causal relationship
between vascular calcifications and osteoporosis may have
great importance in suggesting therapeutic approaches that
may benefit patients with both conditions (8).
This review will focus on the evidence supporting the possibility
that some therapies based on biological linkage may act as
dual-purpose therapies, reducing the risks of bone loss and of
the progression of atherosclerosis.
Bisphosphonates
The bisphosphonates (BP) are approved therapies for the pre-
vention or treatment of osteoporosis and related fractures.
They are currently considered the drugs of choice because of
their demonstrated efficacy and safety in reducing vertebral as
well as non vertebral fracture risk (9). Bisphosphonates are
stable analogues of inorganic pyrophosphate, in which the oxy-
gen bridge of the P-O-P bond has been replaced by a carbon
binding with two additional side chains. The more potent BP
have nitrogen atoms in their side chains. They appear to inhibit
selectively farnesylpyrophosphate, an enzyme downstream of
HMG-coenzyme A in the mevalonate pathway of cholesterol
biosynthesis. BP then inhibit the prenylation of small GPT-bind-
ing proteins, and reduce the synthesis of isoprenoid lipids. BP
not containing amino groups (clodronate and etidronate) do not
interfere with the synthesis of lipids, but are metabolized to a
cytotoxic analogue of ATP, which induces the death also of
cells of osteoclast lineage (10). Several studies reported that
both amino and non-amino BP inhibit the development of ex-
perimental atherosclerosis, an effect that appears independent
of the lowering of cholesterol level in the circulation. Animal
studies have shown that etidronate decreases the amount of
lipid-containing plaques in medium-sized arteries and limits the
proliferation of lipid-laden foam cells in the aorta (11, 12). Intra-
venous clodronate was able to reduce significantly the area of
lipid-stained atheromatous lesions in the aorta of rabbits fed
with high-cholesterol diet (13). Alendronate and ibandronate
(both nitrogen-containing BP) inhibit calcification of arteries and
heart valves in rats treated with warfarin (14). Human studies
seem conflicting. Koshiyama et al. (15) reported a decrease in
carotid intima-media thickness (CIMT) (an early marker of ath-
erosclerosis) in osteopenic type 2 diabetic patients treated for
one year with cyclic etidronate, whereas Delibasi et al. (16) ob-
served no significant change in CIMT in postmenopausal
women with osteoporosis after one year of treatment with alen-
dronate 70 mg/week. A retrospective study on the assessment
of mortality in the patient population from the Risedronate
Phase III Clinical Trial Progamm (17) revealed a trend toward
lower cardiovascular mortality in the ITT group compared with
placebo, largely dependent on a significant reduction in mortali-
ty due to stroke in the risedronate-treated patients.
The biological mechanisms of such effects are not clear. Adami
et al. (18) reported that in osteoporotic women neridronate (an
aminobisphosphonate structurally very similar to pamidronate)
produced a significant decrease in serum LDL-cholesterol and
ApoB with a concomitant increase in serum HDL-cholesterol and
ApoA-I, with non significant changes in mean total cholesterol
and triglycerides. If this effect of neridronate on the lipid profile
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holds for BPs as a class, clinical implications may be relevant
and favourable. A further possible mechanism by which BP may
be protective with respect to cardiovascular morbidity and mor-
tality could be related to a direct effect on arterial wall. BP are
taken up by bone tissue, however they accumulate also in the
arterial walls, regardless of the presence of calcified atheroma-
tous lesions (19). Macrophages and some other endocytotic
cells are able to internalize BP (20), which may then interact with
enzymes in these cells and influence the inflammatory re-sponse
leading to atherosclerosis and further vascular events. Further
studies are needed to evaluate the clinical relevance of such
findings. The possibility to deliver a high concentration of BP to
tissues by encapsulating them in liposomes (8) makes this com-
pounds more available for phagocytosis by macrophages, and
may increase their potential for therapeutic use in patients.
Statins
Statins inhibit 3-hydroxy-3-methylglutaryl-coenzime A (HMG-
CoA) reductase, the limiting step in the cholesterol synthesis
pathway. Statins are largely prescribed worldwide because of
their demonstrated effect to decrease cardiovascular morbidity
and mortality. As a consequence of the inhibition of HMG-CoA
reductase, statins decrease the production of mevalonate, ger-
anyl pyrophosphate, and farnesyl pyrophosphate, then reduc-
ing prenylation of small GTP-binding proteins (21). Statins
share these effects with nitrogen-containing BP, and could in-
hibit inflammation intracellularly interfering with Ras superfami-
ly protein function (22). Like BP, statins can inhibit osteoclast
formation and activity (23), giving powerful evidence for thera-
peutic linkage of atherosclerosis and osteoporosis. Besides the
inhibition of bone resorption, statins also stimulate osteoblasts
differentiation by enhancing expression of bone morphogenetic
protein 2 in cultured osteoblasts, neonatal murine calvaria, and
the cortical bone of mice (24). This finding was confirmed in ex-
perimental and clinical studies (25,26), suggesting that statins
may act as anabolic agents in the bone tissue.
Although several case-control studies have found a beneficial
effect of statins on fractures, no placebo-controlled clinical trial
has been performed to evaluate the effect of statins on fracture
risk. Many studies have evaluated the effects of statins on
bone mineral density (BMD), a less stringent criterion than the
search for an effect on fracture risk, but still a valuable step in
the evaluation of anti-osteoporotic drugs. A recent meta-analy-
sis by Uzzan et al. (27), on the effects of statins on bone miner-
al density, studied the impact of statins on BMD at various sites
and compared the effects of lipophilic and more hydrophilic
statins. This meta-analysis analyzed sixteen studies, which in-
cluded mostly postmenopausal osteoporotic women under
statins. The effect size reached a statistically significant value
for total hip and femoral neck BMD, but not for lumbar spine
BMD. The meta-analysis also showed that lipophilic statins
(simvastatin and lovastatin) had an effect on total hip and
femoral neck BMD significantly greater than more hydrophilic
statins (pravastatin, atorvastatin, and fluvastatin). Favourable
actions of statins on bone may be part of their pleiotropic ef-
fects, which include upregulation of eNOS (the isoform most
widely expressed in bone) (28), inhibition of plasminogen acti-
vator inhibitor-1 (29), activation of protein kinase Akt, a further
inducer of eNOS (30), an over-expression of Kloto mRNA (a
peptide hormone involved in the pathogenesis of osteoporosis
and vascular disease in mice) (31, 32), and an enhanced pro-
duction of OPG by osteoblast (33). A study by Wang et al. (34)
showed that simvastatin can promote fracture healing in
ovariectomized rats when injected in close proximity of the
fracture, a procedure that prevents statins from being stored in
the liver and that results in much higher concentration at the
fracture site. Statins and bisphosphonates have similar mecha-
nisms of action, in that both of them inhibit cholesterol synthe-
sis and cause isoprenoid depletion, which in turn inhibits the
signalling pathway for IL-6 mediated inflammation. Statins and
bisphosphonates inhibit bone resorption, however only statins
might directly stimulate bone formation. One could hypothesize
that combination treatment with statins and BP should be the
most effective strategy for prevention and therapy of athero-
sclerosis, CVD, and osteoporosis. To date, only a study at-
tempting to investigate prospectively whether statins have an
additive effect to BP in producing an increase in lumbar spine
and total hip BMD has been performed (35). This study report-
ed that statins have modest additive effects to bisphospho-
nates in increasing spine BMD, but produced no additive effect
at femoral level.
Although statins would represent a theoretically ideal candidate
as antiosteoporotic drug, large prospective randomized place-
bo-controlled trials are required before acknowledging them in
osteoporosis the same reassuring role they play in cardiovas-
cular disease.
β-blockers
The discovery of the role of leptin in the regulation of bone
mass has given new enphasys on the role of the sympathetic
nervous system in the regulation of bone turnover. Studies in
animals have shown that propranolol antagonizes the negative
effect on bone induced by intracerebral injection of leptin (36).
β-blockers also increased bone formation in ovariectomized
rats (36). It has been reported that β-blockers exert their action
on bone through a stimulation of bone formation and a reduc-
tion of bone resorption (37), the latter as a result of an inhibi-
tion of the stimulating action of sympathetic nervous system on
the beta-adrenergic receptors on osteoblast, which leads to an
overproduction of RANKL. Since β-blockers are widely used in
human disease, and particularly in cardiovascular disease, a
possible effect on bone mass would be of interest with respect
to the treatment of osteoporosis. Two recent epidemiological
studies have shown that the β-blocker use was associated with
a 20-30% decrease in fracture risk (38,39). These data were
not confirmed in the study by Reid et al. (40), who reported an
inconsistent association between β-blocker use and BMD. This
inconsistency may be due to the fact that the effect of sympa-
thetic nervous system on bone depends on several factors like
mechanical loading, muscle mass, and a balance among differ-
ent hormonal effects. More recent papers also provide conflict-
ing results. Bonnet et al. (37) reported that patients taking β-
blockers had higher spine (+3%) and femoral neck (+4%)
BMD, and a 49% reduction in fracture prevalence than con-
trols. Interestingly, β-blocker users had a significant increase in
femoral neck cortical width. Bone parameters differences are
however attenuate if weight is taken into account. Meisinger et
al. (41) studied the association between use of β-blockers and
incidence of fractures in a large population over a mean follow
up period of 10.7 years. They found that the use of β-blockers
was associated with a lower risk of any fracture (odd’s ratio
0.57). Perez-Castrillon et al. (42) prospectically studied a small
sample of 40 patients hospitalized for an acute myocardial in-
farction; 30 of them were treated with cardioselective β-block-
ers. After one year of follow up, no beneficial effect of treat-
ment on BMD or biochemical parameters of bone metabolism
was observed. Although of great interest, available data do not
allow to conclude that β-blockers are expected to exert benefi-
cial effects on bone of such a relevance to recommend the use
for osteoporotic treatment. Ad hoc studies using a less hetero-
geneous population are needed to detect a clear effect of β-
blockers on bone mass.
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Drugs interfering with the OPG/RANKL/RANK system 
The role of the RANK/RANKL/Osteoprotegerin pathway has
been well documented in animal and clinical studies (43-46).
This system is perhaps the best candidate to play a central role
in the bone-arterial wall biological linkage. Breafly, RANKL (Re-
ceptor Activator of Nuclear Factor B Ligand) binds to and acti-
vates its receptor RANK, a protein receptor on the surface of
osteoclast precursor, and induces differentiation, activation and
survival of osteoclasts, thus increasing bone resorption. Osteo-
protegerin (OPG) is a glycoprotein produced by osteoblast,
which acts as a natural inhibitor of RANKL, preventing RANKL
from binding to its osteoclast receptor, and, as a consequence
of this, preventing bone resorption and bone loss. OPG knock-
out mice have severe osteoporosis and present multiple osteo-
porotic fractures, and, surprisingly, also develop severe medial
arterial calcifications. The mechanism by which OPG regulates
calcification in arteries is not fully understood. Min et al. (47) re-
ported that OPG injected into adult mice lacking OPG reversed
the osteoporotic phenotype but did not reduce arterial calcifica-
tion, while the vascular abnormalities were completely rescued
using an OPG transgene approach. Clinical data appear con-
flicting. Kiechl et al. (48) showed a positive association be-
tween high serum OPG levels and serious atherosclerotic vas-
cular disease and mortality. Surprisingly, postmenopausal os-
teoporotic women have serum OPG levels higher than age-
matched controls (49). Since also patients with coronary artery
disease have OPG serum levels higher than healthy subjects
(50), the role of OPG in humans appears more complex than in
animals. A human monoclonal antibody for human RANKL is
under investigation in osteoporotic women (51, 52). If the ani-
mal model holds for human, a reduction in cardiovascular mor-
bidity and mortality should be expected in treated patients. Da-
ta on this point are however not still available.
Conclusions
Available data would suggest that some drugs approved for the
treatment of osteoporosis, and some other drugs known to re-
duce the risk of mortality in cardiovascular disease, may have
dual action in that they could improve bone density, reduce
fracture risk and at the same time limit progression of athero-
sclerosis (Table I). This appears particularly useful in polymed-
icated patients, where the use of a treatment having both car-
diovascular and skeletal beneficial effects would be very use-
ful. The existence of a biological linkage between osteo-porosis
and atherosclerosis, and particularly atherosclerosis with calci-
fications, encourages to designs controlled studies to better
clarify the outcome of such therapies.
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Table I - Therapies which may exert dual-action effects on both cardiovascular and skeletal system.
Therapies Actions on cardiovascular system Actions on bone
Bisphosphonates – Inhibit arterial and heart valves calcification. – Inhibit osteoclast activity
– Lower LDL-cholesterol – Increase bone density
– Reduce fracture risk
Statins – Lower cholesterol – Stimulate osteoblast differentation
– Antiatherogenic – Increase bone density
– Reduce fracture risk?
β-blockers – Control blood pressure – Increase bone density
– Reduce cardiovascular mortality – Reduce fracture risk?
Anti-RANKL antibodies – Uncertain – Decrease osteoclast activity
– Increase bone density
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